Chronic Hepatitis D Virus Infection

SAN DIEGO — Combination tobevibart and elebsiran led to “profound and rapid virologic suppression” as well as normalization of alanine aminotransferase at week 24 in chronic hepatitis D virus infection, according to preliminary data.

In a Healio video exclusive, Anu Osinusi, MD, MPH, reported long-term bulevirtide monotherapy 2 mg and 10 mg remained safe and effective for chronic hepatitis D virus with improved biochemical, fibrosis and virologic markers at 144 weeks.